skip to main content

PEA2

PEA2

Catalogue No.

10032307

Cell Line Name

PEA2

Cell Line Description

PEA2 is an adherent cell line derived from a malignant effusion from the peritoneal ascites of a patient with a poorly differentiated adenocarcinoma. PEA2 was collected on relapse after treatment with cisplatin and prednimustine. PEA2 exhibits poor growth in semi-solid medium (agar). PEA2 is from the same patient as the PEA1 cell line (ECACC Catalogue number 10032306). This cell line is one of nine from the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer, isolated from various malignant sites, and at various treatment stages) available at ECACC which provides a model system for research into the mechanism of oestrogen action on ovarian adenocarcinoma tumour cells, and for the study of efficacy and toxicity of oestrogen protagonists.

General Info

Species

Human

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Receptors

Oestrogen receptor positive cell line. For antigen expression see Langdon SP et.al. (1988) Cancer Research Nov 1; 48(21):6166-72.

Tissue of Origin

Ovary

Morphology

Swirling pattern of cells

Karyotype

For modal chromosome numbers see Langdon SP et.al. (1988) Cancer Research Nov 1; 48(21):6166-72.

Disease

Cystadenocarcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Splitsub-confluent cultures (70-80%) 1:4 to 1:10 seeding at 2- 3 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Doubling time approximately 66 hours.

Culture Medium

RPMI 1640 + 2mM Glutamine + 2mM Sodium Pyruvate + 10% Foetal Bovine Serum (FBS).

Growth Mode

Adherent

Additional Info

Depositor

Licensed from: Cancer Research Technology Ltd Angel Building 407 St John Street London EC1V 4AD

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Langdon SP et.al. (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Research Nov 1; 48(21):6166-72. PMID: 3167863.

Bibliography

Langdon SP et.al. (1990) Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. British Journal of Cancer Aug; 62(2):213-6. PMID: 2386737.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: PEA2 (ECACC 10032307).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.